Menu Search
Equities

Avantor Inc

AVTR:NYQ

Avantor Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)27.70
  • Today's Change0.64 / 2.37%
  • Shares traded4.24m
  • 1 Year change+28.36%
  • Beta1.3230
Data delayed at least 15 minutes, as of Sep 19 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform12
Hold8
Sell0
Strong Sell0

Share price forecast in USD

The 20 analysts offering 12 month price targets for Avantor Inc have a median target of 28.00, with a high estimate of 34.00 and a low estimate of 20.00. The median estimate represents a 1.08% increase from the last price of 27.70.
High22.7%34.00
Med1.1%28.00
Low-27.8%20.00

Earnings history & estimates in USD

On Jul 26, 2024, Avantor Inc reported 2nd quarter 2024 earnings of 0.25 per share. This result was in line with the consensus of the 19 analysts following the company and under-performed last year's 2nd quarter results by 10.71%.
The next earnings announcement is expected on Oct 25, 2024.
Average growth rate-2.27%
Avantor Inc reported annual 2023 earnings of 1.06 per share on Feb 14, 2024.
Average growth rate+21.76%
More ▼

Revenue history & estimates in USD

Avantor, Inc. had 2nd quarter 2024 revenues of 1.70bn. This bettered the 1.70bn consensus of the 18 analysts covering the company. This was 4.35% below the prior year's 2nd quarter results.
Average growth rate-0.58%
Avantor, Inc. had revenues for the full year 2023 of 6.97bn. This was 7.26% below the prior year's results.
Average growth rate+3.96%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.